WHO updated its hepatitis C treatment guidelines to provide recommendations for the use of these new medicines. The objectives of these WHO guidelines are to provide updated evidence- based recommendations for the treatment of persons with hepatitis C infection using, where possible, all DAA-only combinations. The guidelines also provide recommendations on the preferred regimens based on a patient’s HCV genotype and clinical history, and assess the appropriateness of continued use of certain medicines. This document also includes existing recommendations on screening for HCV infection and care of persons infected with HCV that were first issued in 2014.
Archive for category: Tools & Guidelines
In 2014, ANPUD has agreed to partner with HIV/ AIDS Asia Regional Program (HAARP) in supporting the meaningful involvement of people who use drugs (PWUD) in all areas of harm reduction policy and program implementation. This includes developing skills of people who use drugs in Lao PDR, Cambodia and Vietnam through the development and implementation of capacity building activities (including training modules) in consultation with country stakeholders.
The political environment in Asia is hugely adverse to the rights and needs of PWID, and is exacerbated by the War on Drugs policies, high rates of incarceration for drug offences and long periods of detention in well over a 1000 Compulsory Centre's for Drug Users (CCDU) across the region . Because HCV is perceived to affect only PWID, it is difficult to gain political support for action on HCV issues and makes advocacy for humane and effective HCV responses challenging.. ANPUD has found an urgent need for the development of national policy on HCV in Asian countries focused where the need is – among the PWID Community.